23. Recognises the important role played by existing women's networks at various levels, particularly in terms of the local promotion of rural areas and the way they are perceived by the public; draws attention to the need for greater social recognition and for more political and financial support for these networks at local, national and European level, in view of their major contribution to achieving greater equality, particularly as regards training for women in rural areas and the launching of local development projects, including information campaigns on screening to ensure early diagnosis of female cancers (cervical cancer, breast ...[+++] cancer, etc.); calls on the Member States to support increased participation by women in the political process, including their proper representation on the boards of institutions, companies and associations;

23. Recognises the important role played by existing women's networks at various levels, particularly in terms of the local promotion of rural areas and the way they are perceived by the public; draws attention to the need for greater social recognition and for more political and financial support for these networks at local, national and European level, in view of their major contribution to achieving greater equality, particularly as regards training for women in rural areas and the launching of local development projects, including information campaigns on screening to ensure early diagnosis of female cancers (cervical cancer, breast ...[+++] cancer, etc.); calls on the Member States to support increased participation by women in the political process, including their proper representation on the boards of institutions, companies and associations;

While the priority to date has been on mentorship, there will be increasing attention on establishing community coordinator positions to increase families' access to diagnostic teams, services and support.

(Return tabled) Question No. 182 Ms. Chris Charlton: With respect to mental health support in prisons and other detention facilities operated by Correctional Services Canada (CSC): (a) what progress has been made since 2004 in the implementation of the CSC Mental Health Strategy; (b) what plans are in place for the operation of the Community Mental Health and Institutional Mental Health initiatives over the next five years; (c) what plans are in place to act on the recommendations in the 2008-2009 Annual Report of the Office of the Correctional Investigator; (d) what is the total amount of funds allocated to all types of mental health support by CSC for the upcoming fiscal year, broken down by program type; (e) what percentage of overal ...[+++]l CSC funds are allocated to mental health support for the upcoming fiscal year; (f) what percentage of overall CSC funds are allocated to security, risk management and control for the upcoming fiscal year; (g) how many offenders have access to intermediate mental healthcare units in the region in which they are incarcerated; (h) what processes are in place to review the effectiveness of existing mental health programs and identify gaps in services; (i) what recommendations have arisen from such reviews in the last two years; (j) what progress has been made in conducting an independent review of long-term segregation cases; (k) what progress has been made in the creation of a measurable set of performance indicators to evaluate CSC’s response to offender mental health concerns; (l) what guidelines does CSC provide to operational staff on the use of segregation placements with offenders who have mental health concerns; (m) what progress has the National Population Management Committee made in reviewing specific cases of the use of lengthy periods in segregation and treatment alternatives for offenders with mental health concerns; (n) what progress has been made on the creation of a national strategy for managing chronic se ...

[16] The rare disease topics in the 2012 and 2013 FP7 Health Calls were: 'Support for international rare disease research; Clinical utility of –omics for better diagnosis of rare diseases; Databases, biobanks and clinical ‘bio-informatics’ hub for rare diseases; Preclinical and clinical development of orphan drugs; Observational trials in rare diseases; Best practice and knowledge sharing in clinical management of rare diseases (2012) and Development of imaging technologies for therapeutic interventions in rare diseases; New methodologies for clinical trials for small population ...[+++] groups (2013).

The report promotes the following: a global fund financed by G8, the EU, oil-rich nations and others to finance access to and supply of medication and treatment; a global strategy to implement a programme of action to treat and prevent communicable diseases; tiered pricing of medicines from the pharmaceutical industry to ensure wide access to treatment; support for health infrastructure to scan, diagnose, treat and monitor patients, as supply of medicines in itself is inadequate; use of incentives – both financial and legislative – to enhance research and development to produce new medicines and vaccines by both industry and the publ ...[+++]ic sector; the European Commission to work closely with the governments of developing countries, UN agencies, NGOs and civil society to implement the programme.